PSCA CAR V{delta}1 T cells: a safer off-the-shelf CAR T therapy for pancreatic cancer?
Pancreatic cancer remains among the deadliest malignancies, with a 5-year survival of ~13%. Chimeric antigen receptor (CAR) T -cell therapy offers hope, but conventional αβ T cells can trigger severe toxicities, including graft-versus-host …